Prosecution Insights
Last updated: November 20, 2026
Application No. 18/953,275

METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORS

Non-Final OA §103§112
Filed
Nov 20, 2024
Priority
Dec 07, 2016 — provisional 62/431,037 +2 more
Examiner
GRABER, JAMES J
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
THE GENERAL HOSPITAL Corporation
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
93 granted / 200 resolved
-13.5% vs TC avg
Strong +58% interview lift
Without
With
+57.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
60 currently pending
Career history
250
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
35.5%
-4.5% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
29.5%
-10.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 200 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This action is in response to the papers filed October 1, 2026. Election/Restrictions Applicant’s reply filed 10/01/2026 to the Requirement for Restriction/Election mailed 08/19/2026 is acknowledged. Applicant elected without traverse a vector encoding gasdermin D. Claim Listing The instant claim listing was filed 10/01/2026. No amendment has been made relative to the immediate prior version of the claims. Claims 1-20 are pending and under examination. Priority The instant application 18/953,275 was filed on 11/20/2024. This application is a divisional (DIV) of U.S. Application No. 16/466,336 filed 06/04/2019 (now, U.S. Patent No. 12,178,845), which is a national stage of international application PCT/US2017/064809 filed 12/06/2017, claiming priority based on U.S. Provisional Patent Application No. 62/431,037 filed 12/07/2016. Information Disclosure Statement The information disclosure statements (IDS) submitted on 11/20/2024 have been considered. Applicant states that paper copies may be found in the file wrapper of the parent application, U.S. Application No. 16/466,336. Claim Objections Claim 1 is objected to because of the following informalities: In claim 1, the phrase “Apoptosis-associated Speck-like protein comprising a CARD” should be “Apoptosis-associated Speck-like protein containing a CARD” instead. See, e.g., paragraph 9 of the specification. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites a nucleic acid encoding “a cell-type specific promoter, neoplasm cell-specific promoter, and/or tumor cell-specific promoter Schwann cell-specific promoter.” The recitation is found to be indefinite. In this case, the meaning of the phrase “tumor cell-specific promoter Schwann cell-specific promoter” is unclear. It appears there should be a conjunction between the phrase “tumor cell-specific promoter” and the phrase “Schwann cell-specific promote.” For these reasons, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Dependent claims are included in the basis of the rejection because they do not correct the deficiencies of the claim upon which they depend. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-4, 8-11, 14-15 and 17-20 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2016/131981 A1 to Petit et al.; in view of Saukkonen et al. (2004) “Tissue-specific promoters for cancer gene therapy” Expert opinion on biological therapy, 4(5), 683-696. Petit is relevant prior art for disclosing the use of gasdermin, wherein the gasdermin is gasdermin D (GSDMD). See, Abstract. Petit further discloses vectors encoding gasdermin D for in vivo administration, wherein the vector is a viral vector, wherein the viral vector is an adeno-associated viral (AAV) vector, wherein the AAV vector is an AAV1 or AAV9 vector. See, pages 22-24. The gasdermin D is human gasdermin D or mouse gasdermin D. See, page 12. In a working example, an AAV vector was constructed, comprising a CAG promoter operably linked to a gasdermin coding sequence (Dfnb59), wherein the promoter is located upstream of the coding sequence, wherein a PolyA sequence is located downstream of the coding sequence, wherein the vector is flanked by ITR sequences. See, page 55. Petit also discloses pharmaceutical compositions containing the vector encoding gasdermin D and a pharmaceutically acceptable carrier. See, pages 29-30. Petit also discloses kits comprising, in one or more containers in a single package, the vector and/or viral particle and/or pharmaceutical composition. See, page 81. The vector encoding gasdermin D is used to treat cancer, including brain tumors. See, pages 20-21, 23 and 30. Petit does not teach that the promoter is a cell-type specific promoter, neoplasm cell-specific promoter, and/or tumor cell-specific promoter, as claimed in claim 1. Saukkonen is relevant prior art for teaching tissue-specific promoters for cancer gene therapy. Tissue-specific promoters represent a powerful tool for decreasing the toxicity of cancer gene therapy to normal tissues and have previously been utilized for specific mutation compensation or delivery of prodrug-converting enzymes. See, Abstract. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to modify the vector of Petit to contain a tissue-specific promoter for cancer gene therapy, as taught by Saukkonen, with a reasonable expectation of success because Petit’s vector is used for treating cancer, and tissue-specific promoters decrease the toxicity of cancer gene therapy to normal tissues. For these reasons, claims 1-4, 9-10, 14 and 17-20 would have been prima facie obvious over the prior art. Regarding dependent claim 8, Saukkonen discloses human tissue-specific promoters. See, pages 686-688. Regarding dependent claim 11, Petit does not teach the polyadenylation signal is a bovine growth hormone polyadenylation signal, as claimed. However, prior to the effective filing date of the instantly claimed invention, bovine growth hormone polyadenylation signal was a known in the art and routinely used in recombinant protein expression. Official Notice taken, if necessary. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to substitute a polyadenylation signal, as found in Petit, with a bovine growth hormone polyadenylation signal, as previously known in the art, with a reasonable expectation of success because the simple substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Regarding dependent claim 15, AAV vectors, as found in Petit, are single-stranded vectors. For these reasons, dependent claims 8, 11 and 15 also would have been prima facie obvious over the prior art. Claim 16 is rejected under 35 U.S.C. 103 as being unpatentable over Petit and Saukkonen, as applied to the claims above; in further view of McCarty, D. M. (2008) “Self-complementary AAV vectors; advances and applications” Molecular therapy, 16(10), 1648-1656. Regarding dependent claim 16, Petit does not teach the AAV vector is a self-complementary AAV vector, as claimed. McCarty is relevant prior art for teaching that the efficiency of recombinant AAV vectors, in terms of the number of genome-containing particles required for transduction, is hindered by the need to convert the single-stranded DNA (ssDNA) genome into double-stranded DNA (dsDNA) prior to expression. This step can be entirely circumvented through the use of self-complementary vectors, which package an inverted repeat genome that can fold into dsDNA without the requirement for DNA synthesis or base-pairing between multiple vector genomes. The increases in efficiency gained with self-complementary AAV (scAAV) vectors have ranged from modest to stunning, depending on the tissue, cell type, and route of administration. See, Abstract. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to modify the vector of Petit by using a self-complementary AAV vector, as taught by McCarty, with a reasonable expectation of success because self-complementary AAV vectors circumvent the step of convert the single-stranded DNA (ssDNA) genome into double-stranded DNA (dsDNA) prior to expression, thereby significantly increasing transduction efficiency. McCarty further teaches that the scAAV vector comprises a deletion of a terminal resolution site in the first or second AAV inverted terminal repeat. See, pages 1649-1650 and Figure 1. Claims 5-7 and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Petit Saukkonen, as applied to the claims above; in further view of Prabhakar et al. (2013) “Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1” Human gene therapy, 24(2), 152-162. Regarding dependent claims 5, 7 and 12, Petit and Saukkonen do not teach the promoter is a Schwann cell-specific promoter. Prabhakar is relevant prior art for teaching gene therapy for schwannomas using an AAV1 vector encoding caspase-1 (ICE) under the Schwann-cell specific promoter P0. See, e.g., Abstract and Figure 1. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to modify the vector of Petit to contain a Schwann-cell specific promoter, in view of Prabhakar, with a reasonable expectation of success because tissue-specific promoters decrease the toxicity of cancer gene therapy to normal tissues, and one of ordinary skill in the art would have been motivated to alleviate the suffering of subjects having a cancer or tumor of Schwann-cells using gene therapy vectors, as found in Petit. For these reasons, dependent claims 5, 7 and 12 also would have been prima facie obvious over the prior art Regarding dependent claim 6, Prabhakar teaches the Schwann cell-specific promoter is the myelin basic protein (P0) promoter. See, Abstract and Figure 1. Claim 13 is rejected under 35 U.S.C. 103 as being unpatentable over Petit, Saukkonen and Prabhakar, as applied to the claims above; in further view of McCarty, D. M. (2008) “Self-complementary AAV vectors; advances and applications” Molecular therapy, 16(10), 1648-1656. Regarding dependent claim 13, Petit does not teach the AAV vector comprises a deletion of a terminal resolution site in the first or second inverted terminal repeat, as claimed. McCarty is relevant prior art for teaching that the efficiency of recombinant AAV vectors, in terms of the number of genome-containing particles required for transduction, is hindered by the need to convert the single-stranded DNA (ssDNA) genome into double-stranded DNA (dsDNA) prior to expression. This step can be entirely circumvented through the use of self-complementary vectors, which package an inverted repeat genome that can fold into dsDNA without the requirement for DNA synthesis or base-pairing between multiple vector genomes. The increases in efficiency gained with self-complementary AAV (scAAV) vectors have ranged from modest to stunning, depending on the tissue, cell type, and route of administration. See, Abstract. McCarty further teaches that the scAAV vector comprises a deletion of a terminal resolution site in the first or second AAV inverted terminal repeat. See, pages 1649-1650 and Figure 1. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to modify the vector of Petit by introducing a deletion of a terminal resolution site in the first or second AAV inverted terminal repeat, as taught by McCarty, with a reasonable expectation of success because such a modification is made to generate a self-complementary AAV vector, and self-complementary AAV vectors circumvent the step of convert the single-stranded DNA (ssDNA) genome into double-stranded DNA (dsDNA) prior to expression, thereby significantly increasing transduction efficiency. Conclusion The following prior art made of record and not relied upon is considered pertinent to applicant's disclosure: US 2018/0311343 A1 to Huang et al., which claims priority based on U.S. Provisional Patent Application No. 62/412,933 filed 10/26/2016, discloses therapeutic mRNAs encoding gasdermin D (GSDMD) to include pyroptosis and treat cancer. See, e.g., Abstract and paragraph 512 of the publication. See also, pages 1-2 of the provisional application. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES J GRABER whose telephone number is (571)270-3988. The examiner can normally be reached Monday-Thursday: 9:00 am - 4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James D Schultz can be reached at (571)272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES JOSEPH GRABER/Examiner, Art Unit 1631
Read full office action

Prosecution Timeline

Nov 20, 2024
Application Filed
Nov 09, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760278
METHOD FOR OBTAINING ENDOMETRIAL MESENCHYMAL STEM CELLS FROM HUMAN MENSTRUAL BLOOD
4y 0m to grant Granted Oct 13, 2026
Patent 12747440
Antisense oligonucleotides for the treatment of Stargardt disease
1y 11m to grant Granted Sep 29, 2026
Patent 12741034
COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS
1y 10m to grant Granted Sep 22, 2026
Patent 12735711
TARGETING THE HUMAN CCR5 LOCUS AS A SAFE HARBOR FOR THE EXPRESSION OF THERAPEUTIC PROTEINS
3y 9m to grant Granted Sep 15, 2026
Patent 12668612
ONCOLYTIC NON-HUMAN ADENOVIRUSES AND USES THEREOF
4y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
99%
With Interview (+57.6%)
3y 9m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 200 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month